Bosh sahifaALMKT • EPA
add
Mauna Kea Technologies SA
Yopilish kursi
0,18 €
Kunlik diapazon
0,17 € - 0,18 €
Yillik diapazon
0,16 € - 0,53 €
Bozor kapitalizatsiyasi
11,88 mln EUR
Oʻrtacha hajm
104,89 ming
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
EPA
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
(EUR) | iyn, 2024info | Y/Y qiyosi |
---|---|---|
Daromad | 2,13 mln | -40,22% |
Joriy xarajat | 3,51 mln | -5,78% |
Sof foyda | -2,34 mln | -267,42% |
Sof foyda marjasi | -109,77 | -380,03% |
Har bir ulushga tushum | — | — |
EBITDA | -1,76 mln | -559,07% |
Amaldagi soliq stavkasi | — | — |
Balans
Jami aktivlari
Jami passivlari
(EUR) | iyn, 2024info | Y/Y qiyosi |
---|---|---|
Naqd pul va qisqa investitsiyalar | 3,82 mln | -39,56% |
Jami aktivlari | 18,15 mln | -25,14% |
Jami passivlari | 38,49 mln | -5,23% |
Umumiy kapital | -20,34 mln | — |
Tarqatilgan aksiyalar | 64,62 mln | — |
Narxi/balansdagi bahosi | -0,57 | — |
Aktivlardan daromad | -25,45% | — |
Kapitaldan daromad | -56,78% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
(EUR) | iyn, 2024info | Y/Y qiyosi |
---|---|---|
Sof foyda | -2,34 mln | -267,42% |
Operatsiyalardan naqd pul | -1,90 mln | -233,29% |
Sarmoyadan naqd pul | 36,50 ming | 183,91% |
Moliyadan naqd pul | -226,50 ming | -218,90% |
Naqd pulning sof oʻzgarishi | -2,09 mln | -232,96% |
Boʻsh pul | -802,94 ming | -487,16% |
Haqida
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
Tashkil etilgan
2000
Sayt
Xodimlar soni
65